Table of Contents Author Guidelines Submit a Manuscript
Canadian Respiratory Journal
Volume 22, Issue 6, Pages 315-316
Clinico-Pathologic Conferences

Cutaneous Sarcoidosis in a Patient with Severe Asthma treated with Omalizumab

Samuel Yung,1 Duhyun Han,2 and Jason K Lee3

1Department of Medicine, Northern Ontario School of Medicine, Canada
2Victoria College, University of Toronto, Canada
3Division of Clinical Immunology and Allergy, St Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada

Copyright © 2015 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [3 citations]

The following is the list of published articles that have cited the current article.

  • Hiroaki Hayashi, Yuma Fukutomi, Chihiro Mitsui, Kentaro Watai, Yasuhiro Tomita, Yosuke Kamide, Kiyoshi Sekiya, Takahiro Tsuburai, Ayako Horita, Ikuo Saito, Yoshinori Hasegawa, and Masami Taniguchi, “Th1-related disease development during omalizumab treatment: Two cases with severe asthma,” Allergology International, 2017. View at Publisher · View at Google Scholar
  • Duhyun Han, and Jason K. Lee, “Severe Asthma With Eosinophilic Gastroenteritis Effectively Managed by Mepolizumab and Omalizumab,” Annals of Allergy, Asthma & Immunology, 2018. View at Publisher · View at Google Scholar
  • Blake E. Friedman, and Joseph C. English, “Drug-induced sarcoidosis in a patient treated with an interleukin-1 receptor antagonist for hidradenitis suppurativa,” JAAD Case Reports, vol. 4, no. 6, pp. 543–545, 2018. View at Publisher · View at Google Scholar